Study which tests 3 medicines (SB27, EU sourced Keytruda, and US sourced Keytruda) in early or locally advanced non-small cell lung cancer patients who underwent surgery and adjuvant chemotherapy
This clinical trial is looking at three versions of an immunotherapy drug: a proposed biosimilar called SB27, Keytruda sourced from the EU, and Keytruda sourced from the US. Keytruda is a widely used treatment that helps the immune system fight cancer. A biosimilar is a medicine designed to work in the exact same way as an original biological drug, often helping to make treatments more accessible and affordable. The trial is open to adults who have been treated for early or locally advanced non-small cell lung cancer, and who have completed both surgery to remove the tumour and follow-up chemotherapy. Researchers want to compare how these three medicines are absorbed, processed, and cleared by the body (known as bioequivalence), while checking their safety and side effects.
At a glance
What is this study about?
When people are treated for early-stage or locally advanced non-small cell lung cancer, treatment often involves an operation to remove the tumour followed by chemotherapy. In many cases, doctors may then recommend immunotherapy to help stop the cancer from returning. Keytruda (also known as pembrolizumab) is a well-known immunotherapy that works by helping your own immune system recognise and attack cancer cells.
This trial is testing a new medicine called SB27. SB27 is being developed as a 'biosimilar' to Keytruda. Biological medicines like Keytruda are made from living cells, so a biosimilar is not a simple chemical copy, but a highly similar version that must prove it is just as safe and works just as well as the original drug. By developing biosimilars, healthcare systems like the NHS can often access effective treatments at a lower cost.
To make sure SB27 matches Keytruda, researchers are testing it against Keytruda sourced from both European and American supplies. They will measure the levels of the medicine in the blood over time to see if the body handles all three versions in the same way. This helps confirm whether SB27 can be used as a trusted alternative in the future.
Key takeaways
- The study compares a potential new biosimilar (SB27) with standard Keytruda.
- It is for adults who have completed surgery and chemotherapy for non-small cell lung cancer.
- All participants receive an active immunotherapy treatment; there is no placebo.
- The main aim is to confirm that the body handles SB27 the same way it handles Keytruda.
- Participation is entirely voluntary, with regular health and safety monitoring.
Who may be eligible?
You may be able to join this study if you are 18 or older and have been diagnosed with early or locally advanced non-small cell lung cancer. To take part, you must have already had surgery to remove your lung tumour, followed by a course of chemotherapy (known as adjuvant chemotherapy) to lower the chance of the cancer coming back.
Because this study looks closely at how the body processes the medicine, you will need to be in reasonably good general health and recovered from your recent surgery and chemotherapy. Your doctor will check your blood tests, heart, and organ function to ensure it is safe for you to take part.
You may not be eligible if your cancer has spread to distant parts of the body, if you have certain active autoimmune conditions, or if you have experienced severe side effects from previous cancer therapies. The study doctor will review your full medical history with you to see if the trial is a good fit.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- I am aged 18 or over.
- I have been diagnosed with early or locally advanced non-small cell lung cancer.
- I have had surgery to remove the lung tumour.
- I have completed my planned chemotherapy after surgery.
- I feel well enough to attend regular hospital appointments for check-ups and blood tests.
What does participation involve?
If you decide to take part, you will be randomly assigned to receive one of the three study drugs: SB27, EU-sourced Keytruda, or US-sourced Keytruda. The medicine is given as an intravenous (IV) drip into a vein at the hospital clinic. You will have regular appointments where the trial team will take blood samples to measure how much medicine is in your body and how quickly it leaves your system. You will also have routine health checks, including physical exams, blood tests, and scans to monitor your health. The total duration of the study involves several treatment visits and follow-up checks over a number of months to monitor your recovery.
Potential risks and benefits
Locations (2)
- —UnverifiedSpain
- —UnverifiedPoland
Common questions
What is a biosimilar medicine?
A biosimilar is a medicine made to be highly similar to an existing biological drug that is already approved. It goes through rigorous testing to ensure it works just as safely and effectively.
Will I receive an active treatment?
Yes. Every participant in this study receives an active immunotherapy drug—either the new biosimilar SB27 or one of the two standard Keytruda versions. No one receives a dummy drug (placebo).
Do I have to pay to take part?
No. The trial medicine and all trial-related tests are provided free of charge. Some studies also help cover reasonable travel expenses to and from the hospital.
How often will I need to visit the hospital?
You will need to visit the hospital regularly for your infusions, blood tests, and check-ups. The study team will provide you with a clear schedule of visits before you decide to join.
Can I leave the study if I change my mind?
Yes. You have the right to withdraw from the trial at any point, for any reason. Doing so will not affect your relationship with your healthcare team or your future treatment options.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Interested in taking part?
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.